Search This Blog

Wednesday, May 13, 2026

Vor Bio Q1 2026 update: telitacicept Phase 3 on track, cash runway into early 2029

 

Vor Bio Q1 2026 update: telitacicept Phase 3 on track, cash runway into early 2029

  • First-quarter 2026 results highlight on-track enrollment for Phase 3 telitacicept trials in gMG and primary Sjögren’s.
  • UPSTREAM MG topline data for telitacicept expected in 1H 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)